TMEM139 inhibitors pertain to a specialized category of chemical agents that target the transmembrane protein 139 (TMEM139), a protein encoded by the TMEM139 gene in humans. This class of inhibitors is characterized by their selective interaction with the TMEM139 protein, leading to a modulation of its activity. TMEM139, like other transmembrane proteins, spans the lipid bilayer of cells and is involved in various cellular processes due to its location within the cell membrane. The precise biological function of TMEM139, however, remains not fully elucidated, but it is known to play a role in the intricate network of protein-protein interactions that facilitate various cellular functions. TMEM139 inhibitors, therefore, by virtue of their specificity, affect the protein's normal function by binding to it in a manner that alters its activity or stability.
The development of TMEM139 inhibitors is based on a detailed understanding of the protein's structure and the molecular mechanisms governing its interaction with other cellular components. The design of these molecules is typically informed by the three-dimensional conformation of TMEM139, aiming to achieve a high affinity and specificity to the target site. This process often involves the identification of key amino acid residues within the protein that are critical for its activity, and subsequently, inhibitors are tailored to interact with these residues either by mimicking natural ligands or by novel interactions that can modulate the protein's function. The complexity of transmembrane protein structures poses a significant challenge in this endeavor, often requiring advanced techniques such as X-ray crystallography or NMR spectroscopy to unravel the detailed architecture of TMEM139. As a result, the inhibitors designed are a product of sophisticated chemical engineering, utilizing a variety of chemical scaffolds that can range from small molecules to peptides, each designed to fit precisely within the structural context of the target protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an inhibitor of Aurora kinases, which are involved in cell division. Inhibiting these kinases can disrupt the cell cycle, potentially leading to decreased expression or altered function of TMEM139 as its expression may be cell-cycle dependent. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can downregulate protein synthesis by inhibiting the mTORC1 pathway. This could indirectly affect the expression level or function of TMEM139 if it is downstream or modulated by mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can prevent the activation of AKT, thereby affecting the downstream signaling pathways, including those that may regulate the expression or function of TMEM139. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that can disrupt the MAPK/ERK pathway, potentially affecting the expression or function of TMEM139 if it is regulated by this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that impacts cytoskeleton organization and cell motility. This might affect TMEM139 function if it is involved in cellular processes that are dependent on cytoskeletal dynamics. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a V-ATPase inhibitor that prevents acidification of organelles such as lysosomes and endosomes. TMEM139 function could be impacted if it requires acidic conditions or is localized to these organelles. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to ER stress by disrupting calcium homeostasis; it could affect TMEM139 if its function or folding relies on ER-associated processes. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose is a glycolysis inhibitor that can disrupt energy metabolism. This might impact TMEM139 function indirectly if it is energy-dependent or associated with metabolic processes. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C is a DNA crosslinker that can lead to cell cycle arrest. TMEM139 expression or stability could be affected by the changes in the cell cycle progression. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor, which could decrease the overall levels of TMEM139 by inhibiting its translation. | ||||||